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Abstract
Objectives: The aim of this case control genetic association study was to explore whether
two variants within the inducible nitric oxide synthase (iNOS) gene, rs2779249 (C/A) and
rs2248814 (A/G), influenced the risk of Achilles tendinopathy in a British population. Design:
Candidate gene, case control association study. Method: We recruited 145 individuals
diagnosed with Achilles tendon pathology and 132 asymptomatic controls. All participants
were genotyped for the iNOS variants using qPCR and significant associations were 
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discovered using a combination of Chi squared and ANOVA type analysis. Results: The CA 
genotype of the iNOS rs2779249 variant was protective and conformed to a heterozygous 
advantage model of inheritance as it was overrepresented in the control participants
(p=0.009). In sex specific analysis the protective association persisted in male participants
(p=0.016) but not in females. Unlike the rs2779249 variant, the rs2248814 variant was not
associated with Achilles tendinopathy or Achilles tendon rupture. Conclusion: The rs2779249
CA genotype within the human iNOS gene appears to protect individuals from Achilles 
tendinopathy. This study further supports a genetic contribution to modifying the risk of












Nitric Oxide; Genetics; Apoptosis; Inflammation; Achilles Tendon
Practical Implications
 The iNOS rs2779249 genotype could be used to assess risk of Achilles tendon
problems in athletic populations.
 The iNOS rs2779249 genotype might have future application in personalised
treatments for those with Achilles tendon pathologies.
 The inclusion of the iNOS rs2779249 genotype in current injury risk models might
improve the predictive potential of such tests to assess risk.
Abbreviations
ANOVA, one way analysis of variance; ATP, Achilles tendon pathology; iNOS, inducible nitric 
oxide synthase; nNOS, neuronal nitric oxide synthase; eNOS, endothelial nitric oxide
synthase; NOS, nitric oxide synthase; NO, nitric oxide; CON, control; TEN, tendinopathy;
RUP, rupture; SNP, single nucleotide polymorphism; HWE, Hardy Weinberg equilibrium;
GTN, glyceral Trinitrate.
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Achilles tendon pathology (ATP) is a complex, painful, degenerative condition, affecting both 
sporting and sedentary individuals1. 75% of Achilles tendon ruptures are observed in middle
aged sport participating males2. Multiple intrinsic and extrinsic risk factors contribute to ATP
aetiology, and the condition is known to have a genetic3 and, more recently, an epigenetic 
basis4,5 .
The inducible nitric oxide synthase (iNOS) gene is one of three Nitric Oxide Synthase (NOS)
genes (eNOS, nNOS, iNOS)6 responsible for nitric oxide (NO) generation through L arginine
oxidation and catalysed by the NOS enzymes7. NO is a free radical and is associated with 
multiple biological functions8. After tendon injury, NO is induced by all 3 NOS isoforms, with 
upregulated NOS activity reported in tendinopathy in both human and rat models6. Research
suggests that iNOS expression is elevated 23 fold higher than controls four days after
Achilles tendon injury9. Lin and colleagues9 suggest that NO catalysed by the iNOS isoform
of NOS induces apoptosis in inflammatory cells to eradicate the cells from the damaged










An iNOS gene transfection study demonstrated NO’s ability to enhance collagen synthesis in 
tendon cells in vitro10 . The increased collagen synthesis was inhibited when a NOS inhibitor 
was employed. The use of glyceryl trinitrate (GTN) patches containing NO, in conjunction
with rehabilitation, has been studied in a randomised group of patients with Achilles 
tendinopathy in comparison to rehabilitation alone11. It was observed that the addition of the
GTN patch significantly enhanced patient recovery, with 78% of tendons in the GTN group
asymptomatic with daily activities as opposed to 49% in the placebo group (p=0.001). The
addition of GTN patches to patient rehabilitation resulted in reduce pain with activity, and 
patients presented with lower pain scores after performing a hop test.
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In a rat healing model, the administration of NO paracetamol vs two control groups 
(paracetamol group and a vehicle group) was investigated12. Paracetamol had no effect on
healing when compared to the vehicle group. NO paracetamol vs paracetamol alone 
displayed similar failure loads, however, secondary endpoints of Achilles tendon healing
differed between the two groups. At day 10 postoperatively, the NO paracetamol group 
displayed a smaller cross sectional area, a greater dry weight and lesser wet weight, a 
larger collagen content and better organization of collagen, suggesting the addition of NO
increased collagen synthesis and encouraged collagen reorganisation12.
Two iNOS single nucleotide polymorphisms (SNPs) rs2779249 (C/A) and rs2248814 (A/G)
were of interest for this study. These variants are situated within the iNOS gene and its 5’
flanking region on chromosome 17. The rs2779249 SNP is a functional variant -1026 bp 
upstream of the promoter region13. The C allele leads to a 4.73 fold lower transcriptional
activity of the promoter compared to the A allele14. The rs2248814 SNP resides 28,260 bp
downstream of the rs2779249 SNP within the intronic region flanked by exons 12 and 13.
The rs2248814 SNP has been linked to impaired fracture healing15. Sathyendra and
colleagues15 looked at sixty two patients with long bone fractures, thirty three presenting with 
an atrophic nonunion (case group) and twenty nine showing uneventful fracture union










As NO plays an important role in collagen homeostasis within the tendon, we hypothesised
that genetic variability in NO synthesising genes like iNOS could impact on the risk of tendon
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145 Caucasian case (ATP) subjects (56 females, 89 males) were originally recruited from the
County Clinic, Northampton. The subjects’ pathologies were diagnosed using published 
criteria previously described for this cohort and assessed by the clinical author (WJR)16. This 
was based on clinical assessment and confirmed with the appropriate imaging modalities.
Those patients considered for certain management techniques, such as high-volume 
stripping, or for confirmation of rupture underwent ultrasound. Others underwent MRI
analysis. For the purpose of our study, the cohort was subdivided into a rupture subset and a 
chronic tendinopathy subset. For clinical management, the patients were further subdivided 
into complete ruptures, partial ruptures, tendinosis, and para-tendinopathy, however, these
are outside the scope of this paper.
We used the abbreviation ATP to describe a set of combined Achilles tendon pathologies. 
Specifically, the ATP case participant group consisted of an Achilles tendinopathy subset
(TEN) (n=103) and an Achilles rupture subset (RUP) (n=42). The RUP subset included
subjects with partial or complete ruptures to the Achilles tendon. Full details of the specific
pathological definitions for this cohort have previously been published17. In addition to the
cases, 132 asymptomatic, healthy, Caucasian control (CON) participants (49 female, 83










DNA from all participants was isolated as described in our previous study16. For this study we 
re analysed those same samples using TaqMan® SNP genotyping probes, along with
specific forward and reverse primers, for the iNOS gene rs2779249 and rs2248814 SNPs. 
Each reaction contained 10 ng of DNA and each PCR plate contained both positive 
(repeated samples) and negative (non template) controls. Following a holding phase at 95°C
for 10 minutes, PCR runs consisted of 40 cycles of a denaturing stage at 92 °C for 15
seconds and a final annealing stage at 60 °C for 1 minute. Genotypes for each sample were
determined by end point fluorescence and called using StepOne software v2.1.
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IBM SPSS Statistics version 22 (IBM Corporation, Armonk, New York) was used to carry out
independent T tests on the participants characteristics (age, BMI, height and weight)
between the ATP and CON groups, alongside analysis of variance (ANOVA) to determine
whether anthropometric data interacted with genotype for both the ATP and CON groups. 
Pearson’s Chi square analysis or Fisher’s exact test were used to assess differences 
between allele and genotype distributions for both the rs2779249 and rs2248814 variants 
within the ATP and CON groups. A similar analysis was conducted to establish whether any
associations were specific to just tendinopathy (TEN) and/or rupture (RUP) (as opposed to 
the collective pathology of ATP). We also tested whether sex interacted with genotype.
We used the SNPStats online analysis software (available at
https://www.snpstats.net/start.htm) to establish whether alleles at either of the two loci
investigated deviated from Hardy Weinberg equilibrium (HWE). Inferred haplotype analysis 
showing estimated relative frequency was also carried out. Haplotype frequencies were 
measured using an expectation maximisation algorithm. Further details on the software 









Using the Quanto power software (available at http://biostats.usc.edu/cgi-
bin/DownloadQuanto.pl) we calculated that our study would have 81% power to detect
associations at the 0.05 level of significance. All p values reported were unadjusted based on
the rationale presented in our previous studies19 .
All experimental protocols received ethical approval from the Research Ethics Committee of
the Faculty of Health and Society within the University of Northampton, UK. All subjects
provided their written informed consent, in accordance with the Declaration of Helsinki,
alongside the completion of an extensive medical history questionnaire.
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There were no statistical differences between the ATP and CON groups in relation to age,
(p=0.264), height (p=0.067), weight (p= 0.370), and BMI (p=0.736). The ATP group ages 
were self reported age at onset of symptoms. There were no anthropometric interactions with 
the iNOS rs2779249 genotypes (table 1a); height, CON (p=0.183), ATP (p=0.129); weight,
CON (p=0.175), ATP (p=0.886); age, CON (p=0.311), ATP (p=0.606); BMI, CON (p=0.330),
ATP (p=0.843). The iNOS rs2248814 genotypes did not associate with weight (table 1b), 
CON (p=0.110), ATP (p=0.492); age, CON (p=0.085), ATP (p=0.713); BMI, CON (p=0.548),
ATP; (p=0.440), however the iNOS rs2248814 AG genotype associated with height
(p=0.029) in the CON group, but not the ATP group (p=0.915). This variant however, did not
associate with ATP, tendinopathy or rupture.
We found that the iNOS rs2779249 CA genotype was overrepresented in the CON
individuals (protective effect) (p=0.009; OR=0.46; CI 0.27-0.79) (figure 1a). Similarly, the CA
genotype was significantly overrepresented in the control participants compared to the TEN
subset (p=0.005; OR=0.40; CI 0.22-0.74) (figure 1b). However, no associations were noted











We observed the CA genotype of the same variant to be overrepresented in the male CON
participants (p=0.016; OR=0.37; CI=0.18-0.76) (figure 1c), significantly overrepresented in 
the male CON participants in comparison to the male TEN subset (p=0.007; OR=0.30; CI=
0.13-0.69), but not significant in the male RUP subset (p=0.660). There were no significant
differences in the genotype distribution for the iNOS variant rs2779249 when only females 
were compared between the CON and ATP participants (p=0.350), CON and TEN subset
(p=0.330), and CON and RUP subset (p=0.720).
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No significant differences were observed in the genotype distribution of the iNOS gene
rs2248814 variant within all investigated participant subsets; all CON participants and all
ATP participants (p=0.760); female CON and female ATP participants (p=0.500); and male
CON and male ATP participants (p=0.910).
There were no deviations from HWE in the investigated participant groups, except where 
significant differences in the genotype distribution were observed (supplementary table 2).
When this is the case, both the mixed participant sample and the CON participant sample
remained in HWE, however the ATP participant sample violated HWE. Raw haplotype data 
between the CON and ATP participant group can be found in supplementary (supplementary
figure 3). There were no significant haplotypic effects observed, global haplotype association 
p=0.077. There were no significant differences in allele distribution between the entire CON
and entire ATP participant groups for both iNOS rs2779249 (C/A) (supplementary figure 2a)










In this study we found the iNOS rs2779249 variant influenced the risk of ATP in a British
cohort. Specifically, the CA genotype was enriched in the CON participant group, inferring
the genotype as a contributing factor to reducing the risk of ATP. Our results are consistent
with the preliminary findings of a study by Nell and colleagues in 201220. In their study
consisting of 78 individuals diagnosed with Achilles tendinopathy, they reported a marginally
significant protective effect of the CA genotype (p=0.049). In our study we also assessed for
sex differences and observed a significant overrepresentation of the CA genotype in the
male CON participant group. However, this was not observed in females. It is important to
note that genetic variants observed to associate with complex pathologies are contributing
factors to the total risk and are not to be interpreted as directly responsible. Therefore, our
data suggests the rs2779249 CA genotype contributes to a reduction in the risk of Achilles 
tendon injuries.
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It is not fully understood why the iNOS rs2779249 CA variant exerts a protective effect
against ATP, however NO is an important messenger molecule mediating both inflammatory
and apoptotic pathways 21, and an appropriate balance of NO is essential for healthy cellular 
processes22. It is known that the C allele of the rs2779249 variant is associated with a 4.73
fold lower transcriptional activity than the A allele14. Possession of the CC genotype may
infer a state in which NO levels are limited compared to those with the AA genotype. 
Therefore, it might be reasonable to assume that heterozygous CA individuals are producing
an appropriate amount of NO, which may lower the risk of sustaining a tendon injury,
compared to those with the CC or AA genotype who may be producing too little or too much
NO respectively. 
Dakin and colleagues investigated Achilles tendon biopsies from patients to determine
whether an inflammatory process is a feature of Achilles tendinopathy and rupture and
observed evidence of chronic inflammation23. Their investigation found complex macrophage
activation protein signatures and observed target molecules expressed in patient tissue
samples from interferon, NFκB, STAT6 and GCR activation pathways. NFκB’s are known to
control the expression of genes involved in cell adhesion, angiogenesis, apoptosis and the
cell cycle24, and the NFκB family are responsible for initiating expression of iNOS25 and










iNOS is the predominant enzyme from the NOS family involved in inflammation27 and has 
been described as a downstream inflammatory mediator in multiple cell types, including
skeletal muscle cells28. Inducible NO has been highlighted as an important messenger in the
regulation of myogenic precursor cell fate and the inflammatory response, indicating
inflammation dependent muscle healing in a damage/regeneration mouse model28. Also
evidencing that iNOS is scarcely expressed in healthy skeletal muscle28. Animal studies have 
demonstrated the importance of iNOS in promoting tendon healing following injury29. From a
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clinical perspective, there has been interest in the epigenetic modification of iNOS activity in 
controlling symptoms of chronic Achilles tendinopathy. GTN skin patches liberate NO into the
local tissues. It has been shown to be effective in several studies in the management of
tendinopathy30.
Although we have found that the iNOS rs2779249 CA genotype reduces the risk of ATP, our
study does have some limitations. Firstly, although our study is adequately powered to detect
associations in the entire cohort, stratifying by sex would have underpowered this analysis 
and therefore our sex specific data should be viewed with caution. Secondly, our study is 
limited to a single ethnic group and should be repeated in a non Caucasian cohort. Finally, it
is now known that epigenetic factors play a significant part in the predisposition to
musculoskeletal injury4 and therefore further studies should examine the role of DNA












In summary, we have identified the iNOS rs2779249 CA genotype as a protective factor
contributing to reducing the risk of ATP. Although this genotype modifies risk, Achilles tendon 
injuries are complex and likely to arise from multiple interactions between genetic and 
environmental factors (epigenetics). This research enhances our current understanding of
risk factors for ATP, and the iNOS gene remains a suitable candidate for further investigation
regarding tendon pathology.
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Figure 1a: Genotype Frequency distribution of the iNOS variant rs2779249 between the
entire control participant cohort (CON) (N=129) and the entire Achilles tendon pathology
cases (ATP) (N=121).
Figure 1b: Genotype Frequency distribution of the iNOS variant rs2779249 between the
entire control participant cohort (CON) (N=129) and the entire tendinopathy participant 
subset (TEN) (N=93).
Figure 1c: Genotype Frequency distribution of the iNOS variant rs2779249 between the male 











Figure 1: iNOS rs2779249 variant genotype distribution in a British cohort. Significance was 
accepted when p<0.05. Frequency in percentage (%) of cohort analysed and N is the total
number of participants genotypes in each group.
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Table 1a: Characteristics of the entire CON and ATP participant groups for the iNOS variant












CC AA AC CC
Age (years) N 9 54 58 15 31 72
Mean 41.67 43.30 39.91 40.20 44.61 43.19
SD± ± 11.72 ± 13.48 ± 9.62 ± 14.56 ± 12.90 ± 14.33
P Value 0.311 0.606
BMI (kg/m2) N 9 55 57 14 24 49
Mean 24.59 25.44 26.47 26.34 26.40 25.85
SD± ± 3.65 ± 4.90 ± 4.18 ± 5.22 ± 4.53 ± 3.72
P Value 0.330 0.843
Height (cm) N 9 55 57 15 33 71
Mean 170.89 174.07 176.74 171.93 169.76 173.86
SD± ± 11.96 ± 10.04 ± 10.45 ± 10.31 ± 9.96 ± 9.26
P Value 0.183 0.129
Weight (kg) N 9 55 58 14 24 49
Mean 73.00 78.04 83.43 79.14 76.58 78.04
SD± ± 19.16 ± 20.38 ± 18.41 ± 18.22 ± 17.87 ± 14.62
P Value 0.175 0.886
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Table 1b: Characteristics of the entire CON and ATP participant groups for the iNOS variant
rs2248814 using one-way ANOVA analysis stratified according to genotype.
rs2248814 CON ATP
AA AG GG AA AG GG










32 23 59 32
Mean 38.14 41.10 45.09 41.39 44.19 43.19
SD± ± 9.49 ± 11.82 ± 11.73 ± 16.20 ± 13.37 ± 12.97
P Value 0.085 0.713
BMI (kg/m2) N 21 70 32 20 36 27
Mean 26.72 25.49 25.87 25.63 26.79 25.52
SD± ± 4.71 ± 4.56 ± 4.24 ± 2.98 ± 4.58 ± 4.62
P Value 0.548 0.440
Height (cm) N 21 70 32 23 62 31
Mean 179.67 173.04 176.03 172.52 172.68 171.77
SD± ± 7.90 ± 10.37 ± 11.05 ± 11.79 ± 8.65 ± 10.48
P Value 0.029 0.915
Weight (kg)b N 21 70 33 20 36 27
Mean 87.14 77.17 81.15 75.25 80.17 76.41
SD± ± 20.29 ± 19.24 ± 18.86 ± 13.88 ± 16.56 ± 17.72
P Value 0.110 0.492
Table 1 represents the participant characteristic ANOVA results for the iNOS rs2779249 
variant and iNOS rs2248814 variant, stratified according to genotype. Significance was 
accepted when p<0.05. cm: centimetres; kg: kilogrammes; m: metres.
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